These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 27461388)

  • 1. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.
    Dimitriadis GK; Weickert MO; Randeva HS; Kaltsas G; Grossman A
    Endocr Relat Cancer; 2016 Sep; 23(9):R423-36. PubMed ID: 27461388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
    Appetecchia M; Baldelli R
    J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
    Massironi S; Conte D; Rossi RE
    Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
    Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
    Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.
    Anderson JV; Bloom SR
    Scand J Gastroenterol Suppl; 1986; 119():115-28. PubMed ID: 2876495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A; Bhatt V
    Ann Pharmacother; 2012 Jun; 46(6):851-62. PubMed ID: 22589450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
    Hofsli E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotherapies for GEP-NETs.
    Öberg K
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
    Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.
    Srirajaskanthan R; Toumpanakis C; Meyer T; Caplin ME
    Aliment Pharmacol Ther; 2009 Jun; 29(11):1143-54. PubMed ID: 19298583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.
    Toumpanakis C; Caplin ME
    Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours.
    Strosberg JR; Kvols LK
    Expert Opin Investig Drugs; 2007 Feb; 16(2):219-24. PubMed ID: 17243941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
    Weber M
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK; Khan MS; Toumpanakis C; Caplin ME
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
    Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
    Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of neuroendocrine tumours.
    Weber HC
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study.
    Qureshi SA; Burch N; Druce M; Hattersley JG; Khan S; Gopalakrishnan K; Darby C; Wong JL; Davies L; Fletcher S; Shatwell W; Sothi S; Randeva HS; Dimitriadis GK; Weickert MO
    BMJ Open; 2016 May; 6(5):e010765. PubMed ID: 27147385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.